20-409 - KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLCStatus: open
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy Versus Placebo with Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
Patients with Non-Small Cell Lung Cancer
Lung cancer patients with certain mutations in the KEAP1 or NRF2 gene are known to not respond as well to standard immunochemotherapy (treatment that helps the body’s immune system fight cancer in addition to standard chemotherapy) compared with patients who do not have these mutations. This study will test whether an investigational study drug called telaglenastat (CB-839) will be safe and potentially effective for non-small cell lung cancer (NSCLC) when combined with the FDA approved immunochemotherapy regimen of pembrolizumab, carboplatin, and pemetrexed. The combination of telaglenastat, pembrolizumab, carboplatin, and pemetrexed is investigational. All participants in this study will receive the approved recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed.
SponsorsThis trial is sponsored by Calithera.
Providers Associated With This Trial
- Brian E. Persing, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology